Medical Economics
At least one in eight adults in the US has used GLP-1 drugs for weight loss or chronic conditions. Even so, we’re still in the infancy of an era that is both exciting and concerning, as many new and unestablished players are jockeying to command a portion of the GLP-1 market.
In this article in Medical Economics, Michal Conley, General Manager of Certification and Compliance Solutions at LegitScript, discusses how telehealth organizations, med spas, and other nontraditional providers can lead the charge on the safe prescribing of GLP-1 medications.